LMO2, LIM domain only 2, 4005

N. diseases: 83; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 AlteredExpression phenotype BEFREE We also consider the possibility that increased thymic residency time, established under conditions of limited cellular competition, may have contributed to oncogenesis observed in early SCID-X1 trials when combined with insertional activation of proto-oncogenes such as LMO2. 30182300 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 Biomarker phenotype BEFREE Taken together, the data in this study revealed a novel crosstalk between LMO2 and the Wnt signaling pathway during tumorigenesis and suggested that LMO2 might be a tumor suppressor in certain solid tumors, in contrast to its traditional oncogenic role in the hematopoietic system. 27779255 2016
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 Biomarker phenotype BEFREE Taken together, our findings describe novel dual roles of LMO2 to induce tumorigenesis and angiogenesis, and provide potential therapeutic targets in GBMs. 25721045 2015
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 Biomarker phenotype BEFREE LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. 19568416 2009
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 Biomarker phenotype BEFREE This study has investigated LMO2 expression in human prostatic tissue specimens, prostate cancer cell lines, and xenografts; and has assessed the possible role and mechanism of LMO2 in prostate carcinogenesis. 17167821 2007
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 Biomarker phenotype BEFREE We conclude that there is no mandatory role for LMO2 in lymphoid development, implying that its specific role in T-cell tumorigenesis results from a reprogramming of gene expression after enforced expression in T-cell precursors. 14645513 2003
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 GeneticVariation phenotype BEFREE The ectopic expression of LMO1 or LMO2 in T cell acute leukaemias resulting from chromosomal translocations t(11;14)(p15;qll) or t(11;14)(p13;q11) respectively in a causal factor in tumorigenesis. 9872335 1998
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.080 Biomarker phenotype BEFREE Some T cell leukaemia patients have chromosomal abnormalities involving both genes, implying that LMO2 and TAL1 act synergistically to promote tumorigenesis after their inappropriate co-expression. 8605871 1996